19 completed, 10 recruiting, 9 active not recruiting, 7 terminated. 53 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 53 | Completed 19, Recruiting 10, Active not recruiting 9, Terminated 7, Unknown 6, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Adrenal Cortex Diseases: new trials by email Literature Review of Adrenal Cortex Diseases trials Research Report on Adrenal Cortex Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Biospecimen Collection, Cabozantinib, Cemiplimab - Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 48 | 2026-02-22 | 2026-09-18 |
| Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer Cemiplimab - Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 31 | 2025-09-18 | 2025-10-06 |
| Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma Camrelizumab, Apatinib, mitotane - Adrenal Cortical Carcinoma, Adrenal Cortical Cancer | Phase 2 | Recruiting | West China Hospital | 28 | 2025-03-15 | 2025-06-03 |
| Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma Triprolizumab, rodiotherapy - Adrenocortical Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 18 | 2025-03-14 | 2025-04-29 |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate - Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Emory University | 21 | 2025-01-15 | 2026-02-18 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Dostarlimab, Chemotherapy - Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma | Phase 2 | Recruiting | UNICANCER | 120 | 2024-07-23 | 2025-12-02 |
| Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Ablative Radiotherapy, Pembrolizumab - Adrenocortical Carcinoma, ACC | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2023-09-27 | 2026-04-15 |
| A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Mitotane, Pembrolizumab - Adrenocortical Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2023-03-23 | 2025-06-19 |
| Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. Pembrolizumab 25 MG/ML [Keytruda] - Adrenocortical Carcinoma | Phase 2 | Active not recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 24 | 2023-01-31 | 2026-10-20 |
| PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP) - Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2022-10-24 | 2026-10-16 |
| Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC) Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG, Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo - Adrenocortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 80 | 2022-06-08 | 2024-08-01 |
| Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Pembrolizumab / Lenvatinib - Adrenocortical Carcinoma | Phase 2 | Active not recruiting | National Cancer Center, Korea | 30 | 2021-11-15 | 2026-01-23 |
| Milademetan in Advanced/Metastatic Solid Tumors RAIN-32 - Solid Tumors, Head and Neck Carcinoma | Phase 2 | Terminated | Rain Oncology Inc | 40 | 2021-11-01 | 2024-10-17 |
| Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Camrelizumab - Adrenocortical Carcinoma | Phase 2 | Unknown | West China Hospital | 21 | 2020-10-01 | 2024-07-17 |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 1 / Phase 2 | Terminated | Enterome | 70 | 2020-07-23 | 2026-01-30 |
| Cabozantinib in Advanced Adrenocortical Carcinoma Cabozantinib-s-malate - Adrenocortical Carcinoma | Phase 2 | Unknown | Wuerzburg University Hospital | 37 | 2019-06-04 | 2024-08-19 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome relacorilant - Cushing Syndrome | Phase 2 | Active not recruiting | Corcept Therapeutics | 125 | 2018-05-07 | 2026-10-09 |
| Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study - Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 18 | 2018-02-26 | 2024-12-10 |
Showing 20 of 53. Sign in to see all of them.
Adrenocortical Carcinoma (44) · Adrenal Cortex Neoplasms (13) · Pheochromocytoma (7) · Adrenal Gland Neoplasms (6) · Carcinoma, Renal Cell (5) · Paraganglioma (5) · Sarcoma (5) · Cushing Syndrome (4) · Neoplasms (4) · Osteosarcoma (4) · ACTH Syndrome, Ectopic (3) · Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (3) · Cholangiocarcinoma (3) · Hepatoblastoma (3)
Adrenal Gland Diseases (53) · Endocrine System Diseases (53) · Neoplasms by Site (53) · Endocrine Gland Neoplasms (52) · Neoplasms (49) · Adrenal Gland Neoplasms (47) · Neoplasms by Histologic Type (47) · Neoplasms, Glandular and Epithelial (46) · Adenocarcinoma (45) · Carcinoma (45) · Adrenal Cortex Neoplasms (40) · Neoplasms, Germ Cell and Embryonal (13) · Neoplasms, Nerve Tissue (13) · Neuroectodermal Tumors (12)
pembrolizumab (7) · Cisplatin (5) · Mitotane (5) · Magnetic Resonance Spectroscopy (4) · Nivolumab (4) · cabozantinib (4) · Doxorubicin (3) · Specimen Handling (3) · Cytoreduction Surgical Procedures (2) · Etoposide (2) · Ipilimumab (2) · Radiotherapy (2) · apatinib (2) · camrelizumab (2) · cemiplimab (2)
National Cancer Institute (NCI) (12) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (4) · M.D. Anderson Cancer Center (4) · Corcept Therapeutics (2) · Dartmouth-Hitchcock Medical Center (2) · Memorial Sloan Kettering Cancer Center (2) · Novartis Pharmaceuticals (2) · University of Wuerzburg (2) · West China Hospital (2) · Adherex Technologies, Inc. (1) · Arbutus Biopharma Corporation (1) · Burzynski Research Institute (1) · Columbia University (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dana-Farber Cancer Institute (1)
United States (33) · Italy (9) · Germany (6) · Canada (4) · Spain (4) · China (3) · Netherlands (3) · Denmark (2) · France (2) · Hungary (2) · Poland (2) · South Korea (2) · Australia (1) · Austria (1) · Guam (1)
Nitya Raj, MD (2) · Vivek Samnotra, MD (2) · Alfredo Berruti (1) · Alfredo Berruti MD (1) · Alfredo Berruti, MD (1) · Alfredo Berruti, Prof, MD (1) · Andreas G Moraitis, MD (1) · Antonio Fojo, M.D. (1) · Antonio T Fojo, M.D. (1) · Aung Naing (1) · Benedito Carneiro, MD (1) · Bhavana Konda (1) · Bradley A McGregor, MD (1) · Brenda Weigel, MD (1)
PMID 16172198, PMID 22551107, PMID 11745214, PMID 14985252, PMID 16172456, PMID 16580903, PMID 16670169, PMID 1675220, PMID 18491247, PMID 18619560, PMID 18764725, PMID 19223900, PMID 19500762, PMID 21220434, PMID 21612468, PMID 21718784, PMID 21883349, PMID 22156929, PMID 22189997, PMID 22344233, PMID 22837187, PMID 22997446, PMID 23091116, PMID 23370353, PMID 23470964, PMID 24210085, PMID 24268504, PMID 26353009, PMID 2702835, PMID 27626976, PMID 30367443, PMID 30463745, PMID 31276163, PMID 31401903, PMID 31533818, PMID 31644329, PMID 31969335, PMID 32188704, PMID 32303619, PMID 32534809, PMID 32861807, PMID 33216356, PMID 33362722, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33770291, PMID 33882143, PMID 33981288, PMID 34241781
N01CM00038 (2), U10CA098543 (2), 2016 (1), N01CM00070 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62204 (1), N01CM62205 (1), N01CM62207 (1), P30CA060553 (1), P30CA138292 (1), U10CA032102 (1), U10CA180821 (1), U10CA180886 (1)